Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata

Next Previous
Trial Profile

A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Up-AA
  • Sponsors AbbVie

Most Recent Events

  • 16 Jul 2025 The protocol has been amended to add a study 4 and the associated treatment arms.
  • 27 Jan 2025 Status changed from recruiting to active, no longer recruiting.
  • 25 Nov 2024 Planned End Date changed from 3 Jan 2028 to 1 Jan 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top